Lead Product(s) : PATAS
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Newton Biocapital
Deal Size : Undisclosed
Deal Type : Funding
AdipoPharma Secures Funding for Insulin Resistance Clinical Trials
Details : The funding will enable AdipoPharma to accelerate its clinical development of a first-in-class compound, PATAS, that directly targets insulin resistance, the root cause of Type 2 diabetes.
Product Name : PATAS
Product Type : Peptide
Upfront Cash : Undisclosed
November 11, 2024
Lead Product(s) : PATAS
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Newton Biocapital
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $30.0 million
Deal Type : Series A Financing
Details : The proceeds will advance company's lead drug, a potential first-in-class, disease-modifying recombinant protein designed to modulate the Wnt/β-catenin signalling pathway to regenerate pancreatic insulin-producing beta cells ,into clinical development i...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Boehringer Ingelheim GmbH
Deal Size : $30.0 million
Deal Type : Series A Financing
Lead Product(s) : PATAS
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Newton Biocapital
Deal Size : Undisclosed
Deal Type : Series A Financing
French Biotech Company AdipoPharma Secures Series A Funding for Groundbreaking Diabetes Drug
Details : AdipoPharma uses a novel approach to treating Type 2 diabetes. AdipoPharma’s drug, PATAS, treats insulin resistance, the root cause of Type 2 diabetes. PATAS has been designed while working on fat cells known as adipocytes.
Product Name : PATAS
Product Type : Peptide
Upfront Cash : Undisclosed
January 23, 2023
Lead Product(s) : PATAS
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Newton Biocapital
Deal Size : Undisclosed
Deal Type : Series A Financing
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alize Pharma 3 Announces Rebranding to Amolyt Pharma
Details : Amolyt Pharma is developing AZP-3601, a parathyroid hormone analog specifically designed for the treatment of hypoparathyroidism, as well as AZP-3404, a peptide with a new and unique mechanism of action on fat and glucose metabolism.
Product Name : AZP-3601
Product Type : Peptide
Upfront Cash : Inapplicable
February 06, 2020
Lead Product(s) : Eneboparatide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable